151 related articles for article (PubMed ID: 35664355)
1. Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies.
Salami F; Spiliopoulos L; Maziarz M; Lundgren M; Brundin C; Bennet R; Hillman M; Törn C; Elding Larsson H
J Immunol Res; 2022; 2022():3532685. PubMed ID: 35664355
[TBL] [Abstract][Full Text] [Related]
2. Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD
Tavira B; Cheramy M; Axelsson S; Åkerman L; Ludvigsson J; Casas R
Diabetologia; 2017 Jul; 60(7):1276-1283. PubMed ID: 28357504
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial.
Elding Larsson H; Lundgren M; Jonsdottir B; Cuthbertson D; Krischer J;
Pediatr Diabetes; 2018 May; 19(3):410-419. PubMed ID: 29171140
[TBL] [Abstract][Full Text] [Related]
4. GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial.
Krause S; Landherr U; Agardh CD; Hausmann S; Link K; Hansen JM; Lynch KF; Powell M; Furmaniak J; Rees-Smith B; Bonifacio E; Ziegler AG; Lernmark A; Achenbach P
Diabetes Care; 2014 Jun; 37(6):1675-80. PubMed ID: 24598244
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes.
Pihl M; Akerman L; Axelsson S; Chéramy M; Hjorth M; Mallone R; Ludvigsson J; Casas R
Clin Exp Immunol; 2013 Jun; 172(3):394-402. PubMed ID: 23600827
[TBL] [Abstract][Full Text] [Related]
6. GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.
Skoglund C; Chéramy M; Casas R; Ludvigsson J; Hampe CS
Pediatr Diabetes; 2012 May; 13(3):244-50. PubMed ID: 21848927
[TBL] [Abstract][Full Text] [Related]
7. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
Chéramy M; Skoglund C; Johansson I; Ludvigsson J; Hampe CS; Casas R
Clin Immunol; 2010 Oct; 137(1):31-40. PubMed ID: 20580618
[TBL] [Abstract][Full Text] [Related]
8. GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
Ludvigsson J; Chéramy M; Axelsson S; Pihl M; Akerman L; Casas R;
Diabetes Metab Res Rev; 2014 Jul; 30(5):405-14. PubMed ID: 24302596
[TBL] [Abstract][Full Text] [Related]
9. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
Axelsson S; Hjorth M; Akerman L; Ludvigsson J; Casas R
Diabetes Metab Res Rev; 2010 Oct; 26(7):559-68. PubMed ID: 20830731
[TBL] [Abstract][Full Text] [Related]
10. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
Axelsson S; Chéramy M; Hjorth M; Pihl M; Akerman L; Martinuzzi E; Mallone R; Ludvigsson J; Casas R
PLoS One; 2011; 6(12):e29008. PubMed ID: 22174945
[TBL] [Abstract][Full Text] [Related]
11. Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial).
Casas R; Dietrich F; Puente-Marin S; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J
Acta Diabetol; 2022 May; 59(5):687-696. PubMed ID: 35098372
[TBL] [Abstract][Full Text] [Related]
12. Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
Puente-Marin S; Dietrich F; Achenbach P; Barcenilla H; Ludvigsson J; Casas R
Front Immunol; 2023; 14():1112570. PubMed ID: 36817467
[TBL] [Abstract][Full Text] [Related]
13. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
Hjorth M; Axelsson S; Rydén A; Faresjö M; Ludvigsson J; Casas R
Clin Immunol; 2011 Jan; 138(1):117-26. PubMed ID: 21044870
[TBL] [Abstract][Full Text] [Related]
14. Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes.
Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
Diabetes Metab Res Rev; 2022 Mar; 38(3):e3500. PubMed ID: 34611978
[TBL] [Abstract][Full Text] [Related]
15. Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients.
Gorus FK; Balti EV; Vermeulen I; Demeester S; Van Dalem A; Costa O; Dorchy H; Tenoutasse S; Mouraux T; De Block C; Gillard P; Decochez K; Wenzlau JM; Hutton JC; Pipeleers DG; Weets I;
Clin Exp Immunol; 2013 Jan; 171(1):82-90. PubMed ID: 23199327
[TBL] [Abstract][Full Text] [Related]
16. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Wherrett DK; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Greenbaum CJ; Herold KC; Marks JB; Monzavi R; Moran A; Orban T; Palmer JP; Raskin P; Rodriguez H; Schatz D; Wilson DM; Krischer JP; Skyler JS;
Lancet; 2011 Jul; 378(9788):319-27. PubMed ID: 21714999
[TBL] [Abstract][Full Text] [Related]
17. GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells.
Arif S; Gomez-Tourino I; Kamra Y; Pujol-Autonell I; Hanton E; Tree T; Melandri D; Hull C; Wherrett DK; Beam C; Roep BO; Lorenc A; Peakman M
Diabetologia; 2020 Jun; 63(6):1186-1198. PubMed ID: 32248243
[TBL] [Abstract][Full Text] [Related]
18. Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.
Tavira B; Barcenilla H; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
J Diabetes Res; 2018; 2018():9391845. PubMed ID: 30009185
[TBL] [Abstract][Full Text] [Related]
19. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.
Axelsson S; Chéramy M; Akerman L; Pihl M; Ludvigsson J; Casas R
Diabetes Care; 2013 Nov; 36(11):3418-24. PubMed ID: 23863909
[TBL] [Abstract][Full Text] [Related]
20. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
Ludvigsson J; Faresjö M; Hjorth M; Axelsson S; Chéramy M; Pihl M; Vaarala O; Forsander G; Ivarsson S; Johansson C; Lindh A; Nilsson NO; Aman J; Ortqvist E; Zerhouni P; Casas R
N Engl J Med; 2008 Oct; 359(18):1909-20. PubMed ID: 18843118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
